Press release

Datesort ascending Press release
10/08/2017 - 17:45 CET Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA
27/07/2017 - 17:45 CET Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA
05/07/2017 - 18:00 CET Inventiva Announces First-half 2017 Financial and Corporate Update
29/06/2017 - 18:00 CET Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference
20/06/2017 - 18:00 CET Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models
06/06/2017 - 18:00 CET Inventiva to Present at the Jefferies 2017 Global Healthcare Conference
31/05/2017 - 18:20 CET Résultat des votes de l’Assemblée Générale du 29 mai 2017 (Only in french)
30/05/2017 - 7:30 CET Dr Nanna Lüneborg, Principal of Novo Ventures, joins Inventiva’s Board
15/05/2017 - 18:15 CET Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337
25/04/2017 - 18:00 CET Inventiva: first-quarter 2017 financial update
20/04/2017 - 8:01 CET Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress™ 2017 (EASL)
10/04/2017 - 18:14 CET Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis (SSc)
27/03/2017 - 7:30 CET Inventiva: acceleration of the clinical development activities and consolidation of the financial position in 2016
17/03/2017 - 8:47 CET Inventiva Announces the Implementation of a Liquidity Contract with Oddo & Cie (only in french)
17/03/2017 - 8:30 CET Inventiva’s confirms the success of its IPO. Over-allotment option partially exercised
14/02/2017 - 8:13 CET Inventiva raises €48 million in a successful initial public offering on Euronext Paris
02/02/2017 - 7:14 CET Inventiva launches its initial public offering on the regulated market of Euronext Paris
13/01/2017 - 8:19 CET Inventiva files an update to its document de base with a view to its initial public offering
03/01/2017 - 16:30 CET Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
19/09/2016 - 19:10 CET Inventiva Announces Receipt of €2.3 million in Grant Funding for YAP/TEAD Protein Research Program